DOCA-PHARMA
Sources: the KBO register on 20-11-2026; the National Bank, 2025 annual accounts filed on 24-07-2026; the Belgian Official Gazette, latest deed of 12-09-2024.
Grounds
the facts the verdict rests on, each with its source- In 2025, DOCA-PHARMA made a loss of €64,546.Annual accounts 2025 page 2
- Equity is negative: -€79,753 on 31-12-2025.Annual accounts 2025 page 2
- Cash fell from €38,344 to €1,237. Debts due within one year rose from €4,490 to €62,137.Annual accounts 2024 and 2025 page 2
- Of the €152,137 of debt, €90,000 runs for more than a year.Annual accounts 2025, notes page 2
- The 2025 accounts reached the National Bank 7 days before the end of the term.National Bank, filing of 24-07-2026 page 4
Representation
The signing rule is in the founding deed of 12-09-2024.
Articles of association, Belgian Official Gazette of 12-09-2024, deed 24427889
Ownership
The accounts in the micro format list no shareholders. founded DOCA-PHARMA by deed of 12-09-2024. There is one other shareholder.
Deed of 12-09-2024
Financial situation
Annual accounts 2024 to 2025, as filed with the National Bank
Gross margin and net resultin euro
Equity and debtsin euro
Cashin euro
| Financial year | 20243 months | 2025 | Trend |
|---|---|---|---|
| Results | |||
| Gross margin | -€18,752 | -€27,380 | |
| Operating result | -€20,186 | -€63,874 | |
| Net result | -€20,208 | -€64,546 | |
| Balance sheet at the closing date | |||
| Equity | -€15,208 | -€79,753 | |
| Debts | €104,490 | €152,137 | |
| Debts due after more than one year | €100,000 | €90,000 | |
| Debts due within one year | €4,490 | €62,137 | |
| Cash | €38,344 | €1,237 | |
| Balance sheet total | €89,282 | €72,384 | |
| Operations | |||
| Employees in full-time equivalents | - | 1.0 | |
| Ratios | |||
| Solvency | -17.0% | -110.2% | |
| Liquidity | 9.79 | 0.47 | |
Source: Annual accounts 2025, micro format, filed on 24-07-2026 (2026-00326447); Annual accounts 2024, micro format, filed on 14-07-2025 (2025-00264005).
Debts rose by €47,647 in 2025, of which €884 to suppliers.
The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.
DOCA-PHARMA states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from -€18,752 to -€27,380.
The financial year to 31-12-2024 ran for 3 months.
Board, signature and ownership
Position on 20-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts
Who represents the company
The signing rule is in the founding deed of 12-09-2024.
Articles of association, Belgian Official Gazette of 12-09-2024, deed 24427889
Board
Ownership and group
Shareholders
The accounts in the micro format list no shareholders. founded DOCA-PHARMA by deed of 12-09-2024. founded DOCA-PHARMA by deed of 12-09-2024.
Deed of 12-09-2024
Events and comparison
Every event since the founding, newest first
Annual accounts 2025 filed, 7 days before the deadline.
NBB filingAnnual accounts 2024 filed, 17 days before the deadline.
NBB filingIncorporation. Founding capital of €5,000, 100 shares. Founded by and . (director) and (director) appointed. Published on 12-09-2024.
Gazette, deed 24427889First establishment. Edgar Tinelstraat 11, Sint-Niklaas.
Comparable companies, two years later
In July 2024, 7,656 companies had the same profile as DOCA-PHARMA has now: micro, 2 to 5 years old, negative equity and a loss of 10% of the balance sheet or more. Two years later 84.7% were still trading, 6.5% had stopped another way and 8.8% had gone bankrupt.
The return on assets of DOCA-PHARMA, -89.2%, is lower than at 95% of the 1,634 companies filing micro accounts in veterinary activities (NACE 75) in 2025.
Other findings
Peppol
Reachable for e-invoices, under 0208:1013386219.
Sanctions lists
Staff
1 employee on 31-12-2025, 0.6 full-time equivalents on average over the year.
Sources and method
Where each fact in this report comes from
| Source | What | Date | Reference |
|---|---|---|---|
| KBO register | Registration, legal situation, activity, establishment units | 20-11-2026 | KBO 1013.386.219 |
| National Bank of Belgium | Annual accounts 2025, micro format | 24-07-2026 | 2026-00326447 |
| National Bank of Belgium | Annual accounts 2024, micro format | 14-07-2025 | 2025-00264005 |
| Belgian Official Gazette | Founding deed with the articles of association | 12-09-2024 | deed 24427889 |
| Peppol Directory | Registration for e-invoices | 0208:1013386219 | |
| Sanctions lists EU, UN, US (OFAC) and UK | Comparison of the name | 19-11-2026 | |
| Checked | Checked score, bankruptcy probability, credit, comparable companies | 19-11-2026 | bankruptcy model of 2 October 2026 |
Method
Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.
Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 19-11-2026.
Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.
Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.
The scores and ratios are Checked's own calculations, not a credit decision.